Theradiag (France) Today
| ALTHE Stock | EUR 0.37 0.03 8.82% |
Performance5 of 100
| Odds Of DistressLess than 28
|
Theradiag is selling at 0.37 as of the 21st of November 2024; that is 8.82% up since the beginning of the trading day. The stock's last reported lowest price was 0.32. Theradiag has about a 28 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Theradiag SA are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of December 2022 and ending today, the 21st of November 2024. Click here to learn more.
Theraclion SA develops, manufactures, and markets Echopulse ultrasound medical imaging tool for the non-invasive and ambulatory treatment of breast fibroadenomas and benign thyroid nodules to practitioners. The company was founded in 2004 and is based in Malakoff, France. The company has 28.8 M outstanding shares. More on Theradiag SA
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Theradiag Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Theradiag's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Theradiag or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) |
Theradiag SA (ALTHE) is traded on Euronext Paris in France and employs 28 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 20.16 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Theradiag's market, we take the total number of its shares issued and multiply it by Theradiag's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Theradiag SA operates under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 28.8 M outstanding shares.
Theradiag SA has accumulated about 938.86 K in cash with (3.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.11.
Check Theradiag Probability Of Bankruptcy
Ownership AllocationTheradiag SA shows a total of 28.8 Million outstanding shares. Theradiag SA maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Theradiag Ownership Details
Theradiag SA Risk Profiles
Although Theradiag's alpha and beta are two of the key measurements used to evaluate Theradiag's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.64 | |||
| Semi Deviation | 2.62 | |||
| Standard Deviation | 4.31 | |||
| Variance | 18.61 |
Theradiag Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Theradiag without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
| All Next | Launch Module |
Theradiag Corporate Management
Elected by the shareholders, the Theradiag's board of directors comprises two types of representatives: Theradiag inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theradiag. The board's role is to monitor Theradiag's management team and ensure that shareholders' interests are well served. Theradiag's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theradiag's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yann Duchesne | Ex Chairman | Profile | |
| Roberta Brocardo | Ex Officer | Profile | |
| Jose AbellanMartinez | VP Devel | Profile | |
| Anja Kleber | VP Access | Profile | |
| David Auregan | Chief Officer | Profile | |
| Gaylord Tallec | Director Operations | Profile | |
| Michel MD | VP Officer | Profile |
Additional Tools for Theradiag Stock Analysis
When running Theradiag's price analysis, check to measure Theradiag's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theradiag is operating at the current time. Most of Theradiag's value examination focuses on studying past and present price action to predict the probability of Theradiag's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theradiag's price. Additionally, you may evaluate how the addition of Theradiag to your portfolios can decrease your overall portfolio volatility.